| Document Date: 2008-09-18 20:34:44
Open Document File Size: 38,63 KBShare Result on Facebook
City SOUTH SAN FRANCISCO / Tokyo / DEERFIELD / / Company Astellas Astellas Pharma US Inc. / Theravance Inc. / Astellas Pharma US Inc. / Astellas Pharma Inc. / GlaxoSmithKline plc / TD / / Country Japan / United States / Canada / / Event Conference Call / Business Partnership / FDA Phase / / IndustryTerm biopharmaceutical / manufacturing practices / manufacturing / pharmaceutical products / pharmaceutical / / MedicalCondition bacterial infections / gastrointestinal motility dysfunction / hospital-acquired pneumonia / serious Gram-positive bacterial infections / skin and skin structure infections ( csssis ) / MRSA infections / serious Gram-positive infections / respiratory disease / / Organization U.S. Food and Drug Administration / American Medical Association / FDA / Centers for Disease Control and Prevention / / Person Rick E Winningham / / / Position Chief Executive Officer / global category leader / / Product Telavancin / / ProvinceOrState Illinois / California / / PublishedMedium the Journal of the American Medical Association / / Technology drug discovery / anti-infectives / / URL www.theravance.com / www.astellas.com/us / /
SocialTag |
Theravance Receives FDA Approvable Letter for Telavancin for the Treatment of Complicated Skin and Skin Structure Infections SOUTH SAN FRANCISCO, CA and DEERFIELD, IL/OCTOBER 22, 2007 – Theravance, Inc. (NASDAQ: THRX)